Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
Strasbourg, France, October 5, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG) , a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting preclinical data with PoxSTG-EEV , a novel enveloped oncolytic virus designed for systemic delivery, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting . SITC 2026 will take place November 4 - 8, 2026, in Phoenix, Arizona (USA).